Arrowhead Pharmaceuticals Inc (ARWR) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Total Cash From Operating Activities Chart for Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc (ARWR) operating cash flow for FY2025 was USD 179.6M. Arrowhead Pharmaceuticals Inc's operating cash flow grew from USD 4.6K in 1997 to USD 179.6M in 2025 (3935717.6% over 28 years).

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.67B
Implied Share Price
$61.54
Enterprise Value
$8.84B
Revenue (TTM)
$669.49M
EBITDA
-$200.64M
Profit Margin
-47.79%
Trailing P/E
—
Forward P/E
111.11
Price/Book (MRQ)
20.55
Price/Sales (TTM)
12.98
EV/EBITDA
27.85
EV/Revenue
13.37
Dividend Yield
—
Book Value
$3.30
Free Cash Flow (FY2025)
$156.89M
Free Cash Flow Yield
1.81%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.